Timely confirmation of gastroesophageal reflux disease via pH monitoring: Estimating budget impact on managed care organizations

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1317-1327

  Lee, Won Chan ^a   Yeh, Y C ^a   Lacy, B E ^b   Pandolfino, J E ^c   Brill, J V ^d   Weinstein, M L ^e   Carlson, A M ^f   Williams, M J ^g   Wittek, M R ^g   Pashos, C L ^a  

^a ABT ASSOCIATES   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Predictive Health LLC   (United States)

^e Metropolitan Gastroenterology Group PC   (United States)

^f Data Intelligence Consultants LLC   (United States)

^g MEDTRONIC INC   (United States)

Author keywords

Budget impact model; Cost; Gastro esophageal reflux disease; GERD; pH monitoring

Indexed keywords

ANXIOLYTIC AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; ENZYME INHIBITOR; PROTON PUMP;

ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; FINANCIAL MANAGEMENT; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; PH; UNITED STATES; ADULT; AGED; BUDGET; COST OF ILLNESS; DRUG ANTAGONISM; ECONOMICS; ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; FEMALE; INSTRUMENTATION; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PREDICTION AND FORECASTING; RISK ASSESSMENT; STATISTICAL MODEL;

ADULT; AGED; BUDGETS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ENZYME INHIBITORS; ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; PROTON PUMPS; RISK ASSESSMENT; UNITED STATES;

EID: 44349127821     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X280680     Document Type: Article

References (36)

1. Russo MW, Wei JT, Thiny MT, et al. Digestive and liver diseases statistics, 2004. Gastroenterology 2004;126:1448-53
2. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200
3. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007;102:668-85
4. Ali MA, Lacy BE. Esophageal manometry and pH monitoring: gastroenterologists' adherence to published guidelines. J Clin Gastroenterol 2005;39:584-90
5. Lowe RC, Wolf MM. The pharmacological management of gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2004;50:227-37
6. Pohland CJ, Scavnicky SA, Lasky SS, et al. Lansoprazole overutilization: methods for step-down therapy. Am J Manag Care 2003;9:353-8
7. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000;18:20-6
8. Patti MG, Gorodner MV, Galvani C, et al. Spectrum of esophageal motility disorders: implications for diagnosis and treatment. Arch Surg 2005;140:442-8
9. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium dijficile diarrhoea. J Hosp Infect 2003;54:243-5
10. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. J Am Med Assoc 2004;292:1955-60
11. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 2006;296:2947-53
12. des Varannes SB, Mion F, Ducrotte P, et al. Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo). Gut 2005;54:1682-6
13. Pandolfino JE, Zhang Q, Schreiner MA, et al. Acid reflux event detection using the Bravo wireless versus the Slimline catheter pH systems: why are the numbers so different? Gut 2005;54:1687-92
14. Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003;98:740-9
15. Wong WM, Bautista J, Dekel R, et al. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring - a randomized trial. Aliment Pharmacol Ther 2005;21:155-63
16. Lacy BE, O'Shana T, Hynes M, et al. Safety and tolerability of transoral bravo capsule placement after transnasal manometry using a validated conversion factor. Am J Gastroenterol 2007;102:24-32
17. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2005;3:329-34
18. Hall J, Dodd S, Durkin M, et al. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care 2002;11:14-8
19. Kaplan-Machlis B, Spiegler GE, Zodet MW, et al. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000;9:624-30
20. Ofman JJ, Yamashita BD, Siddique RM, et al. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care 2000;6:905-16
21. Sonnenberg A, Inadomi JM, Becker LA. Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1003-13
22. Harewood GC, Gostout CJ. Cost analysis of endoscopic antireflux procedures: endoluminal application vs. radiofrequency coagulation vs. treatment with a proton pump inhibitor. Gastrointest Endosc 2003;58:493-9
23. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices - Budget Impact Analysis. Value Health 2007;10:336-47
24. van PB, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;19:3 [CD002095]
25. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999;231:3-8
26. Anon. Redbook drug topics. Thomson Healthcare Inc.; 2006
27. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100:283-9
28. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;40:20-4
29. Ahlawat SK, Novak DJ, Williams DC, et al. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system. J Clin Gastroenterol 2006;40:20-4
30. Wenner J, Johnsson F, Johansson J, et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol 2007;102:239-45
31. Anon. Pharmacy benefit report facts and figures. East Hanover (NJ): Novartis Pharmaceuticals; 2003
32. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006;101:2128-38
33. Cohen J, Safdi MA, Deal SE, et al. Quality indicators for esophagogastroduodenoscopy. Am J Gastroenterol 2006;101:886-91
34. Sipkoff M. As drug payment model changes, confusion grows among insurers. Managed Care 2007;16(2):56-9
35. Locke GR III, Zinsmeister AR, Fett SL, et al. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005;17:29-34
36. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-79